Taysha Gene Therapies (TSHA) Non Operating Income (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Non Operating Income data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 1096.3% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (up 50.62% YoY), and the FY2025 full-year result was $1.5 million, down 30.45% from the prior year.
• Non Operating Income climbed to $1.1 million in Q1 2026, from $449000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $64.0 million in Q4 2023 to a low of -$100.8 million in Q3 2023.
• A 5-year average of -$2.1 million and a median of $199000.0 in 2022 frame the typical range for Non Operating Income.
• Peak annual rise in Non Operating Income reached 32054.27% in 2023, while the deepest fall reached 9324.02% in 2023.
• Tracing TSHA's Non Operating Income over 5 years: stood at $199000.0 in 2022, then soared by 32054.27% to $64.0 million in 2023, then tumbled by 98.21% to $1.1 million in 2024, then slumped by 60.85% to $449000.0 in 2025, then jumped by 139.64% to $1.1 million in 2026.
• Business Quant data shows TSHA's Non Operating Income at $1.1 million in Q1 2026, $449000.0 in Q4 2025, and $1.3 million in Q3 2025.